PCI Pharma Services has announced the installation and validation of its latest comprehensive serialisation system at its manufacturing Centre of Excellence in Tredegar, UK.
Tredegar
This latest investment shows the company’s continued efforts to increase and expand its serialisation capabilities for the support of customers in advance of the implementation dates for the European Falsified Medicines Directive (EU FMD). Additionally, the company has the capacity to supply to the US and emerging markets.
Commenting on this latest investment, Jim Neville, director of Operations, Tredegar, stated: “This is an important addition to the site’s capabilities. Being able to offer this fully flexible service and work in partnership with our customers to deliver a trusted, seamless service is critical, and being ahead of the timelines with this offering ensures compliance with the EU FMD.”
The flexible technology installed at the Tredegar site, delivers machine and human-readable coding, tamper evident solutions and Bollini labeling — which in turn is linked to a case loading and aggregation station, with a final aggregation station connecting cases to pallet. The company strongly supports use of aggregation in support of product security.
This investment in PCI’s Tredegar facility is part of a global initiative by the company to develop the serialisation services across its global network, which will ultimately exceed more than 90 lines.